Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.

A woman had a severe skin reaction from the drug imiquimod, used for skin cancer, highlighting the need for awareness of rare but serious side effects.

The treatment temporarily improved symptoms of hyperandrogenism in adolescents.

Ritlecitinib can help about 14,000 people with severe hair loss.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

Some IBD patients on anti-TNFs developed severe skin issues, but ustekinumab helped.

A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.

The document concludes that an experimental drug may help wound healing in Epidermolysis Bullosa, links Hydroa vacciniforme to EBV, discusses diagnosing hair loss disorders, finds many children with eczema have allergies, reviews the safety of a skin medication in children, notes side effects of a Duchenne's treatment, and identifies a marker for pediatric mastocytosis.

New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.

Dupilumab can cause lupus-like symptoms, so patients need careful monitoring.

Adalimumab effectively stabilized severe folliculitis decalvans, preventing further hair loss and inflammation.

Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.

IL-23 inhibitors may help treat other skin conditions, but more research is needed.

Dupilumab may help treat hair loss and skin color loss in some patients with atopic dermatitis.

The combination of oral PUVA and corticosteroids helps regrow hair in severe alopecia areata.

Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.

Tofacitinib can be effective in treating hair loss caused by alopecia areata.

Methotrexate effectively controls eye inflammation in Japanese patients with non-infectious uveitis but requires careful monitoring for side effects.

Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.

Distinguishing drug-induced lupus from systemic lupus is challenging and requires careful monitoring.

Secukinumab can cause hair loss, which may improve after stopping the medication.

Deuruxolitinib is FDA-approved for treating severe alopecia areata.

Promising cancer treatments were found, but the manufacturer closed.

Topical ruxolitinib may help some skin conditions but needs more research for alopecia areata.

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

ZD1839 (Iressa) causes skin and hair side effects, treatable with tretinoin cream and minocycline.

Targeting ornithine decarboxylase can help prevent skin cancer.

Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.

Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.